Emerging therapies for inv (16) AML
S Surapally, DG Tenen… - Blood, The Journal of the …, 2021 - ashpublications.org
Blood, The Journal of the American Society of Hematology, 2021•ashpublications.org
The core binding factor composed of CBFβ and RUNX subunits plays a critical role in most
hematopoietic lineages and is deregulated in acute myeloid leukemia (AML). The fusion
oncogene CBFβ-SMMHC expressed in AML with the chromosome inversion inv
(16)(p13q22) acts as a driver oncogene in hematopoietic stem cells and induces AML. This
review focuses on novel insights regarding the molecular mechanisms involved in CBFβ-
SMMHC–driven leukemogenesis and recent advances in therapeutic approaches to target …
hematopoietic lineages and is deregulated in acute myeloid leukemia (AML). The fusion
oncogene CBFβ-SMMHC expressed in AML with the chromosome inversion inv
(16)(p13q22) acts as a driver oncogene in hematopoietic stem cells and induces AML. This
review focuses on novel insights regarding the molecular mechanisms involved in CBFβ-
SMMHC–driven leukemogenesis and recent advances in therapeutic approaches to target …
Abstract
The core binding factor composed of CBFβ and RUNX subunits plays a critical role in most hematopoietic lineages and is deregulated in acute myeloid leukemia (AML). The fusion oncogene CBFβ-SMMHC expressed in AML with the chromosome inversion inv(16)(p13q22) acts as a driver oncogene in hematopoietic stem cells and induces AML. This review focuses on novel insights regarding the molecular mechanisms involved in CBFβ-SMMHC–driven leukemogenesis and recent advances in therapeutic approaches to target CBFβ-SMMHC in inv(16) AML.
ashpublications.org
